Steroidal 5α-Reductase and 17α-Hydroxylase/17,20-Lyase (CYP17) Inhibitors Useful in the Treatment of Prostatic Diseases

The document from 2013 reviews the use of steroidal inhibitors targeting 5α-reductase and CYP17 enzymes in the treatment of prostatic diseases such as benign prostatic hyperplasia (BPH) and prostate cancer (PC). It discusses the clinical use of finasteride and dutasteride, which are 5α-reductase inhibitors, and their impact on reducing prostatic volume and improving urinary symptoms in BPH. The paper also covers the development of CYP17 inhibitors, including abiraterone acetate, which was FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) treatment. The document highlights the challenges in designing these inhibitors, the importance of understanding enzyme structure for drug design, and the need for more studies to establish their role in BPH and PC prevention. It also mentions the potential association of 5α-reductase inhibitors with high-grade cancers and the importance of evaluating inhibitors using human enzymes. The document does not provide specific numbers of people involved in the studies, as it is a general review rather than a report on a specific clinical trial.